172 related articles for article (PubMed ID: 34476551)
21. To evaluate prognostic significance of metabolic-derived tumour volume at staging 18-flurodeoxyglucose PET-CT scan and to compare it with standardized uptake value-based response evaluation on interim 18-flurodeoxyglucose PET-CT scan in patients of non-Hodgkin's lymphoma (diffuse large B-cell lymphoma).
Gupta N; Singh N
Nucl Med Commun; 2020 Apr; 41(4):395-404. PubMed ID: 32073552
[TBL] [Abstract][Full Text] [Related]
22.
Minamimoto R; Fayad L; Vose J; Meza J; Advani R; Hankins J; Mottaghy F; Macapinlac H; Heinzel A; Juweid ME; Quon A
Eur J Nucl Med Mol Imaging; 2021 Aug; 48(9):2883-2893. PubMed ID: 33909086
[TBL] [Abstract][Full Text] [Related]
23. Combination of Deauville score and quantitative positron emission tomography parameters as a predictive tool of anti-CD19 chimeric antigen receptor T-cell efficacy.
Guidetti A; Dodero A; Lorenzoni A; Pizzamiglio S; Argiroffi G; Chiappella A; Bagnoli F; Marasco V; Carniti C; Monfrini C; Seregni E; Pennisi M; Verderio P; Alessi A; Corradini P
Cancer; 2023 Jan; 129(2):255-263. PubMed ID: 36385707
[TBL] [Abstract][Full Text] [Related]
24. Prognostication of diffuse large B-cell lymphoma patients with Deauville score of 3 or 4 at end-of-treatment PET evaluation: a comparison of the Deauville 5-point scale and the ΔSUVmax method.
Ng DZ; Lee CY; Lam WW; Tong AK; Tan SH; Khoo LP; Tan YH; Chiang J; Chang EW; Chan JY; Poon EY; Somasundaram N; Farid H Rashid M; Tao M; Lim ST; Yang VS
Leuk Lymphoma; 2022 Jan; 63(1):256-259. PubMed ID: 34665693
[TBL] [Abstract][Full Text] [Related]
25. Combined Visual and Semiquantitative Evaluation Improves Outcome Prediction by Early Midtreatment
Györke T; Carr R; Cerci JJ; Meneghetti C; Redondo F; Celli M; Gorospe C; Auewarakul CU; Jorgov L; Paez D; Fanti S
J Nucl Med; 2020 Jul; 61(7):999-1005. PubMed ID: 31757842
[TBL] [Abstract][Full Text] [Related]
26. Impact of germline polymorphisms in genes regulating glucose uptake on positron emission tomography findings and outcome in diffuse large B-cell lymphoma: results from the PETAL trial.
Broecker-Preuss M; Becher-Boveleth N; Müller SP; Hüttmann A; Hanoun C; Grafe H; Richter J; Klapper W; Rekowski J; Bockisch A; Dührsen U
J Cancer Res Clin Oncol; 2022 Oct; 148(10):2611-2621. PubMed ID: 34708297
[TBL] [Abstract][Full Text] [Related]
27. The prognostic role of end-of-treatment FDG-PET/CT in diffuse large B cell lymphoma: a pilot study application of neural networks to predict time-to-event.
Annunziata S; Pelliccioni A; Hohaus S; Maiolo E; Cuccaro A; Giordano A
Ann Nucl Med; 2021 Jan; 35(1):102-110. PubMed ID: 33094420
[TBL] [Abstract][Full Text] [Related]
28. [Values of Different Evaluation Criteria of Interim
Zhu LT; Cen XN; Ou JP; Qiu ZX; Wang LH; Liu W; Wang WS; Dong YJ; Liang ZY; Wang MJ; Xu WL; Sun YH; Wang Q; Yin Y; Ren HY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):431-437. PubMed ID: 28446288
[TBL] [Abstract][Full Text] [Related]
29. [Prognostic value of pretreatment (18)F-FDG PET-CT for patients with advanced diffuse large B-cell lymphoma].
Ding CY; Guo Z; Sun J; Yang WP; Li TR
Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):528-533. PubMed ID: 30060362
[No Abstract] [Full Text] [Related]
30. Interim PET/CT based on visual and semiquantitative analysis predicts survival in patients with diffuse large B-cell lymphoma.
Li X; Sun X; Li J; Liu Z; Mi M; Zhu F; Wu G; Lan X; Zhang L
Cancer Med; 2019 Sep; 8(11):5012-5022. PubMed ID: 31293092
[TBL] [Abstract][Full Text] [Related]
31. End-of-Treatment PET/Computed Tomography Response in Diffuse Large B-Cell Lymphoma.
Kostakoglu L; Nowakowski GS
PET Clin; 2019 Jul; 14(3):307-315. PubMed ID: 31084771
[TBL] [Abstract][Full Text] [Related]
32. Bone marrow 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography cannot replace bone marrow biopsy in diffuse large B-cell lymphoma.
Adams HJ; Kwee TC; Fijnheer R; Dubois SV; Nievelstein RA; de Klerk JM
Am J Hematol; 2014 Jul; 89(7):726-31. PubMed ID: 24711255
[TBL] [Abstract][Full Text] [Related]
33. Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma.
Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
Eur J Haematol; 2015 Jun; 94(6):532-9. PubMed ID: 25311082
[TBL] [Abstract][Full Text] [Related]
34. Interobserver Agreement on Automated Metabolic Tumor Volume Measurements of Deauville Score 4 and 5 Lesions at Interim
Zwezerijnen GJC; Eertink JJ; Burggraaff CN; Wiegers SE; Shaban EAIN; Pieplenbosch S; Oprea-Lager DE; Lugtenburg PJ; Hoekstra OS; de Vet HCW; Zijlstra JM; Boellaard R
J Nucl Med; 2021 Nov; 62(11):1531-1536. PubMed ID: 33674403
[TBL] [Abstract][Full Text] [Related]
35.
Cui Y; Jiang Y; Deng X; Long W; Liu B; Fan W; Li Y; Zhang X
Acad Radiol; 2023 Jul; 30(7):1408-1418. PubMed ID: 36437191
[TBL] [Abstract][Full Text] [Related]
36. Improved prediction of chemoresistance in patients with diffuse large B-cell lymphoma through a new interim positron emission tomography-computed tomography evaluation model.
Xie W; Liu MK; Jiang XF; Gao XD; Li B; Wang L; Zhao WL
Acta Oncol; 2021 Jun; 60(6):735-743. PubMed ID: 33720799
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma.
Zhou M; Chen Y; Huang H; Zhou X; Liu J; Huang G
Oncotarget; 2016 Dec; 7(50):83544-83553. PubMed ID: 27835875
[TBL] [Abstract][Full Text] [Related]
38. Baseline
Aide N; Fruchart C; Nganoa C; Gac AC; Lasnon C
Eur Radiol; 2020 Aug; 30(8):4623-4632. PubMed ID: 32248365
[TBL] [Abstract][Full Text] [Related]
39. Four cycles of R-CHOP followed by two applications of rituximab based on negative interim PET/CT: an analysis of a prospective trial.
Jin J; Ji D; Xia Z; Xue K; Zhang Q; Liu Y; Cao J; Hong X; Gu JJ; Guo Y; Lv F
BMC Cancer; 2022 Apr; 22(1):403. PubMed ID: 35418080
[TBL] [Abstract][Full Text] [Related]
40. Functional Parameters of
Yang J; Zhu S; Pang F; Xu M; Dong Y; Hao J; Ma X
Contrast Media Mol Imaging; 2018; 2018():8659826. PubMed ID: 30363729
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]